IMCR as reported
Immunocore Holdings plc reported $413M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.
$413M
Revenue, trailing twelve months · to Q1 2026 · every figure below is as filed, with no scoring applied
- Net Income
- −$28M
Net Income · +27% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$31M
Free Cash Flow · −218% year on year · trailing twelve months to Q1 2026
- Op Margin
- −8.5%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $413M | n/a | Q1 2026 |
| Net Income | −$28M | +27% | Q1 2026 |
| EPS | −$0.55 | +28% | Q1 2026 |
| Gross Margin | 99% | n/a | Q1 2026 |
| Op Margin | −8.5% | n/a | Q1 2026 |
| Net Margin | −6.8% | n/a | Q1 2026 |
| ROE | −7.2% | n/a | Q1 2026 |
| ROA | −2.6% | n/a | Q1 2026 |
| Free Cash Flow | −$31M | −218% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Immunocore Holdings plc (IMCR) - Revenue & ProfitRevenue & ProfitImmunocore Holdings plc (IMCR)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com